Key Stats for Jazz Pharmaceuticals Stock
- 52-Week Range: $97.5 to $200.2
- Current Price: $194.2
- Street Mean Target: $223.5
- Street High Target: $275
- TIKR Model Target (Dec. 2030): $230.3
What Happened?
Jazz Pharmaceuticals (JAZZ), the Ireland-based biopharma focused on rare sleep disorders, epilepsy, and oncology, is executing one of the more underappreciated earnings recovery stories in specialty pharma: the stock trades near $194 while normalized EPS is forecast to rebound from $8.38 in 2025 to $24.06 in 2026, a 187% recovery driven by the simultaneous ramp of four commercial franchises.
Q4 2025 earnings reported on February 24 delivered record quarterly revenue of $1.2 billion, up 10% year over year, beating the consensus estimate of $1.165 billion, with Xywav (low-sodium oxybate for narcolepsy and idiopathic hypersomnia) posting its highest-ever quarterly revenue at $465 million, up 16% versus the prior-year period.
The most structurally significant development in the quarter was not the revenue beat but the zanidatamab regulatory milestone: in Q1 2026, Jazz completed its supplemental BLA submission to the FDA for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma (GEA), a rare stomach and esophageal cancer with a median five-year survival rate below 10%, with the FDA granting both real-time oncology review and breakthrough designation, pointing toward a potential H2 2026 approval and launch.
Renée Galá, President and Chief Executive Officer, stated on the Q4 2025 earnings call that “2025 was a truly transformational year for Jazz,” citing practice-changing Phase 3 data showing zanidatamab delivered more than two years of median overall survival in first-line HER2-positive GEA, a result she described as unprecedented for this patient population.
Looking out three to five years, Jazz is building toward multiple $1 billion-plus franchises simultaneously: Epidiolex (cannabidiol for rare epilepsies) secured patent protection into the very late 2030s after ANDA settlements, Modeyso (dordaviprone for a rare brain cancer with no prior drug options) carries a $500 million-plus peak U.S. sales estimate, and the zanidatamab program targets a combined peak revenue opportunity exceeding $2 billion across GEA, breast cancer, and pan-tumor indications.
Wall Street’s Take on JAZZ Stock
The 2025 earnings collapse was a one-year accounting event, not a business event; the forward picture is a company with four commercial franchises growing simultaneously and a major approval catalyst expected within months.
Jazz Pharmaceuticals’ normalized EPS is forecast to reach $24.06 in 2026 and $25.07 in 2027, built on $4.45 billion and $4.80 billion in revenue respectively, with the epilepsy and oncology portfolio (Epidiolex, Modeyso, Ziihera) expected to grow double digits, partially offsetting pressure on the high-sodium oxybate products from generic competition in the rare sleep franchise.
Fifteen analysts hold buy or outperform ratings on Jazz Pharmaceuticals stock, with only two holds and no sells, a consensus structure that reflects high conviction: the mean target of $223.50 implies 15% upside from current levels, while the $275 Street high target suggests the bull case is anchored to a successful zanidatamab GEA launch and continued Modeyso momentum.
The $188 low target and $275 high target represent a $87 spread, and that debate is essentially one binary: whether zanidatamab wins first-line GEA market share quickly and positions Jazz to file for breast cancer, or whether the sleep franchise erosion from generic oxybate entry accelerates faster than the oncology ramp.
Priced at roughly 8x the fiscal 2026 normalized EPS estimate of $24.06, Jazz Pharmaceuticals stock sits well below specialty pharma peers trading at 12x to 15x forward earnings, even as EPS is forecast to nearly triple from the depressed 2025 base, leaving Jazz Pharmaceuticals stock appearing undervalued given the combination of a pipeline inflection and a multiple that has not moved to reflect it.
If generic high-sodium oxybate volumes build faster than expected in H2 2026 and payers begin redirecting narcolepsy patients, Xywav revenue could undershoot the $1.7 billion to mid-single-digit growth target, compressing the earnings recovery Wall Street is pricing in.
The zanidatamab PDUFA date, expected after the Q1 2026 submission, is the single data point to watch: approval with a clean label covering first-line GEA would confirm the $2 billion-plus peak revenue thesis and likely re-rate the multiple; a complete response letter or label restriction would reset the timeline and pressure the $223.50 mean target.
Jazz Pharmaceuticals Stock Financials
Jazz Pharmaceuticals grew total revenue to $4.27 billion in fiscal 2025, up 4.9% year over year, marking the company’s 21st consecutive year of top-line revenue growth even as a GAAP net loss of $356 million obscured the underlying commercial momentum.
Operating income reached $1.02 billion in fiscal 2025, up 17.8% year over year, as the combination of Xywav’s 12% growth, Epidiolex crossing $1 billion for the first time, and Modeyso contributing $48 million in its first partial year pushed operating margins from 21.2% in fiscal 2024 to 23.9% in fiscal 2025.
Gross margins held at 91.7%, essentially flat with the prior three years despite the addition of Modeyso and Ziihera, both of which carry higher royalty burdens, a signal that the core portfolio’s pricing power is absorbing the mix shift without structural margin degradation.
What Does the Valuation Model Say?
The TIKR model’s mid-case target of $230.34 is built on a 6.7% revenue CAGR through December 2030 and net income margins expanding to 36.4%, inputs that look conservative given Jazz’s current operating margin trajectory and a zanidatamab GEA launch that is not yet generating a full year of revenue in the model’s base period.
A stock trading at 8x forward earnings while normalized EPS nearly triples is the kind of disconnect the TIKR model was built to surface: the $230.34 mid-case target implies JAZZ is undervalued relative to the earnings recovery already underway, before the zanidatamab GEA opportunity is fully priced.
Whether JAZZ closes the gap to the $223.50 Street mean or re-rates toward the $275 high depends on whether the oncology ramp overtakes the sleep franchise headwind fast enough to sustain double-digit EPS growth beyond the 2026 recovery year.
What Has to Go Right
- Zanidatamab receives FDA approval in H2 2026 with a label covering first-line HER2-positive GEA; Jazz CFO Phil Johnson confirmed at the March TD Cowen conference that the sBLA submission is complete and PDUFA clock has started
- Modeyso sustains its launch trajectory: 360-plus patients treated in roughly 4.5 months of 2025 puts the $500 million-plus peak U.S. sales estimate increasingly within reach, per management commentary at the February earnings call
- Xywav holds flat to mid-single-digit growth in 2026 as the IH patient base (over 5,000 active IH patients at year-end 2025, up 34% year over year) offsets narcolepsy headwinds from two entering high-sodium oxybate generics
- Normalized EPS reaching $25.07 in fiscal 2027 at even a 10x multiple would put JAZZ at $250, well above the current Street mean
- TIKR model high case of $278.64 assumes a 7.4% revenue CAGR and 38.2% net income margins, achievable if GEA launch exceeds expectations and breast cancer data read out favorably in late 2027 or early 2028
What Could Go Wrong
- Generic oxybate adoption accelerates faster than payer step-edits can contain it: Jazz guided Xywav flat to up mid-single digits, but acknowledged H2 2026 is where competitive dynamics from generics and potential new wake-promoting agents converge
- Zanidatamab receives a complete response letter or a narrower-than-expected label in GEA, deferring the most significant revenue catalyst by 6 to 12 months and compressing the 2026 EPS estimate back toward $20
- The TIKR model low case of $186.42 implies virtually no upside from current levels and requires only a 6.0% revenue CAGR with 34.4% net margins, a scenario that becomes plausible if both the sleep franchise and the GEA launch disappoint simultaneously
- Xywav payer renegotiation risk is real: CFO Phil Johnson noted at the March Barclays conference that payers could come back to the table if generic volumes build meaningfully, and even partial step-edit programs in prior test accounts showed physicians will navigate through them, but at the cost of some conversion friction
Should You Invest in Jazz Pharmaceuticals plc?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up JAZZ stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Jazz Pharmaceuticals plc alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze JAZZ stock on TIKR for Free →
